Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate (S1P). Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quanti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Ottenlinger, Florian M., Mayer, Christoph A., Ferreirós, Nerea, Schreiber, Yannick, Schwiebs, Anja, Schmidt, Katrin G., Ackermann, Hanns, Pfeilschifter, Josef M., Radeke, Heinfried H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2016
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5093125/
https://ncbi.nlm.nih.gov/pubmed/27857690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00412
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky